Administrative Core

行政核心

• 批准号: 9151285
• 负责人: Michael S Gilmore
• 金额: $ 15.71万
• 依托单位: MASSACHUSETTS EYE AND EAR INFIRMARY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9151285
• 关键词: Anabolism; Antibiotic Resistance; Biochemistry; Biology; Cell Wall; Center for Translational Science Activities; Clinical Sciences; Clinical Treatment; Communication; Communities; Complement; Complex; Development; Ear; Enterococcus; Eye; Faculty; Fostering; General Hospitals; Genus staphylococcus; Goals; Individual; Infection; Knowledge; Massachusetts; Modeling; Molecular Biology; Multi-Drug Resistance; National Institute of Allergy and Infectious Disease; Participant; Pathogenesis; Prevention; Research Infrastructure; Resistance; Resources; Science; Scientist; Sum; System; Technology; Toxic effect; Universities; catalyst; data sharing; design; experience; implementation research; inhibitor/antagonist; medical schools; methicillin resistant Staphylococcus aureus; microbial; multi-drug resistant pathogen; multidisciplinary; next generation; novel; novel strategies; pathogen; prevent; programs; screening; success; tool

SUMMARY This Harvard-wide Program on Antibiotic Resistance (HPAR) proposal outlines the design and function of a novel, multidisciplinary, collaborative partnership to develop new approaches for treating and preventing multidrug resistant MRSA and VRE infection. Although discovery and delivery of novel and promising new compounds to the development pipeline is a major overall goal, because this is an academic effort, we also will add to the scientific knowledge that underpins the novel inhibitors developed; add to the understanding of resistance; and develop novel new tools for studying host-pathogen interactions and multidrug resistant pathogens. This project is being proposed by an accomplished group of scientists with extensive experience in the biochemistry of cell wall biosynthesis and use of that information to design screens and new inhibitors; the molecular biology of model host systems and the use of those systems in novel ways for screening compounds that hit complex targets with minimal toxicity; the development and application of high throughput next generation technologies; and the pathogenesis, biology and clinical treatment of infection caused by multidrug resistant staphylococci and enterococci. This scientific expertise is complemented by substantial administrative experience. The goal of the HPAR Administrative Core therefore is to oversee the smooth implementation of the research plan and deployment of resources, and to foster the cohesive and well functioning whole to achieve goals that are greater than the sum of the individual projects. This will be accomplished by achieving the following Specific Aims: 1) Provide program management, oversight, and compliance assurance, 2) Facilitate interactions between participants from the various components of the Harvard Medical School (including faculty located on the Longwood Campus, at Massachusetts General Hospital, and the Massachusetts Eye and Ear Infirmary), and the Mylonakis lab now in part at Brown University – in a smooth and effective manner; 3) Provide critical infrastructure for fiscal management of the program; 4) Provide connectivity to and leverage other Harvard-wide initiatives, including the Microbial Sciences Initiative (MSI), and Catalyst Clinical and Translational Sciences Center; and 5) Provide a single point of contact and active coordination for on-going communication with NIAID, the Program Officer, and other NIAID staff and initiatives. The Administrative Core has managed the previous period in a way that led to a highly functioning, well integrated, and synergistic whole, and achieved additional aims generating resources and fostering data sharing with the greater scientific community. The proposed continuation period will build on these successes.

总结 哈佛大学抗生素耐药性计划（HPAR）的提案概述了一个 新的、多学科的合作伙伴关系，以开发新的治疗和预防方法 多重耐药MRSA和VRE感染。虽然发现和交付的新颖和有前途的新的 化合物的开发管道是一个主要的总体目标，因为这是一个学术的努力，我们也将 增加了支持开发的新型抑制剂的科学知识;增加了对 耐药性;并开发研究宿主-病原体相互作用和多药耐药的新工具 病原体这个项目是由一组有着丰富经验的科学家提出的， 细胞壁生物合成的生物化学和利用这些信息来设计筛选和新的抑制剂; 模型宿主系统的分子生物学和这些系统在筛选化合物的新方法中的应用 以最小的毒性击中复杂的目标;高通量的开发和应用 多药耐药引起感染的发病机制、生物学和临床治疗 耐药葡萄球菌和肠球菌。这一科学专门知识得到了大量行政管理人员的补充。 体验.因此，HPAR管理核心的目标是监督 研究计划和资源调配，并促进整体的凝聚力和良好运作， 实现比单个项目的总和更大的目标。这将通过实现 以下具体目标：1）提供项目管理、监督和合规性保证，2） 促进来自哈佛医学院各个组成部分的参与者之间的互动 （包括位于长木校区的教师，在马萨诸塞州总医院，和 马萨诸塞州眼耳医院），以及目前部分位于布朗大学的Mylonakis实验室-在一个平稳的 3）为该计划的财政管理提供关键基础设施; 4）提供 连接并利用其他哈佛范围内的倡议，包括微生物科学倡议（MSI）， 和Catalyst临床和转化科学中心;以及5）提供单点联系和主动 协调与NIAID、项目官员和其他NIAID工作人员和倡议的持续沟通。 行政核心在前一时期的管理方式导致了一个高度运作的、良好的 整合，协同整体，并实现了额外的目标，产生资源和促进数据 与更大的科学界分享。拟议的延续期将以这些成功为基础。